Utidelone plus Capecitabine for residual triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two oral chemotherapy drugs (Utidelone and Capecitabine) for women with triple-negative breast cancer that did not fully disappear after standard chemo before surgery. The goal is to see if this treatment can lower the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older.
- Your breast cancer is triple-negative (estrogen, progesterone, and HER2 negative).
- You had chemotherapy before your surgery but some cancer remained (either in the breast or nearby lymph nodes).
- Your previous chemo included drugs like anthracycline or taxane.
- You are in generally good health, with normal blood, kidney, and liver function.
- You have no other active cancers, serious heart or lung problems, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether adding capecitabine to pembrolizumab after surgery can lower the risk of cancer coming back in people with triple-negative breast cancer that didn’t fully respond to earlier treatment. It’s meant for patients whose tumor was removed but still showed remaining cancer after chemo-immunotherapy.
This trial tests whether adding a study drug called UTD1 to capecitabine can shrink or control breast cancer that has spread to the brain. It’s for people with HER2-negative metastatic breast cancer who have brain metastases and meet specific safety and lab requirements.
This study tests whether adding utidelone (an investigational drug) to capecitabine (a standard chemo pill) after surgery can reduce the chance of breast cancer returning in patients with triple-negative breast cancer who still had cancer cells after neoadjuvant chemotherapy. Participation could help improve your treatment plan to lower the risk of recurrence.
This trial tests a new chemotherapy combination (utidelone plus capecitabine) versus a standard taxane plus capecitabine for HER2-negative breast cancer. The goal is to see if the new combo works better and has fewer side effects.
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
This trial tests whether adding more treatment after surgery can help people with triple-negative breast cancer who still have cancer cells left after initial chemotherapy and immunotherapy. It aims to reduce the chance of cancer coming back.
Hear when a new Triple Negative Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.